TRUMENBA targets a gene found in >99% of invasive MenB disease strains2

TRUMENBA works by targeting both subfamilies, A and B, of a lipoprotein—factor H binding protein (fHBP)—for which the gene is found in more than 99% of invasive MenB strains.2

The fHBP Discovery

Pfizer used a combined biochemical and immunological screening approach to identify surface-expressed proteins on MenB strains that were capable of producing antibodies that could kill diverse meningococcal strains. During this process, fHBP elicited robust bactericidal responses.1

Contact your Pfizer Sales Representative or call a Vaccine Specialist at